TY - JOUR
T1 - Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes
T2 - a prospective cohort study
AU - for the Renal Insufficiency and Cardiovascular Events (RIACE) Study Group
AU - Penno, Giuseppe
AU - Solini, Anna
AU - Orsi, Emanuela
AU - Bonora, Enzo
AU - Fondelli, Cecilia
AU - Trevisan, Roberto
AU - Vedovato, Monica
AU - Cavalot, Franco
AU - Zerbini, Gianpaolo
AU - Lamacchia, Olga
AU - Nicolucci, Antonio
AU - Pugliese, Giuseppe
AU - Laviola, Luigi
N1 - Funding Information:
This research was supported by the Research Foundation of the Italian Diabetes Society (Diabete Ricerca) and the Diabetes, Endocrinology and Metabolism (DEM) Foundation, and by unconditional grants from Eli-Lilly, Sigma-Tau, Takeda, Chiesi Farmaceutici, and Boehringer-Ingelheim. The funding sources had no role in the study’s design, conduct, and reporting .
Funding Information:
G.Pe.: lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sigma-Tau, and Takeda, and travel grants from AstraZeneca, Novo Nordisk, and Takeda; A.S.: consulting fees from AstraZeneca, Boehringer Ingelheim, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and MundiPharma; E.O.: consulting fees from Eli Lilly and Novo Nordisk; E.B.: consulting fees from Abbot, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Bruno Farmaceutici, Eli Lilly, Janssen, Johnson&Johnson, Merck Sharp & Dohme, MundiPharma, Novartis, Novo Nordisk, Roche, Sanofi-Aventis, Servier, and Takeda, and research grants from AstraZeneca, Genzyme, Menarini Diagnostics, Novo Nordisk, Roche, and Takeda; C.F.: lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk and travel grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Sanofi-Aventis, and Takeda; R.T.: consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; M.V.: lecture fees from Lifescan and Novo Nordisk; F.C.: lecture fees from AstraZeneca, Sanofi-Aventis, and Takeda; G.Z.: research grants from NTC Pharma and Omikron Italia; O.L.: consulting fees from Astra-Zeneca, Boehringer Ingelheim; lecture fees from Astra-Zeneca, Eli-Lilly, Merck-Sharp&Dohme, Sigma-Tau, Sanofi-Aventis, Takeda; grant support from Astra-Zeneca; A.N.: consulting fees from AstraZeneca, Pikdare, and Roche, lecture fees from AstraZeneca, Boehringer Ingelheim, Medtronic, and Novo Nordisk, and research grants from Aboca, AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi-Aventis, and Theras; G.Pu.: consulting fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly, lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, MundiPharma, Novartis, Novo Nordisk, Sigma-Tau, Takeda, and travel grants from AstraZeneca, Laboratori Guidotti, Sanofi-Aventis, and Takeda.
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/12
Y1 - 2021/12
N2 - Background: It is unclear whether insulin resistance (IR) contributes to excess mortality in patients with type 2 diabetes independent of diabetic kidney disease (DKD), which is strongly associated with IR and is a major risk factor for cardiovascular disease (CVD), the main cause of death in these individuals. We tested this hypothesis in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events Italian Multicentre Study. Methods: This observational, prospective, cohort study enrolled 15,773 patients with type 2 diabetes attending 19 Italian Diabetes Clinics in 2006–2008. Insulin sensitivity was assessed as estimated glucose disposal rate (eGDR), which was validated against the euglycaemic-hyperinsulinemic clamp technique. Vital status on October 31, 2015, was retrieved for 15,656 patients (99.3%). Participants were stratified by eGDR tertiles from T1 (≥ 5.35 mg/kg/min) to T3 (≤ 4.14 mg/kg/min, highest IR). Results: CVD risk profile was worse in T2 and T3 vs T1. eGDR tertiles were independently associated with micro- and macroalbuminuria and the albuminuric DKD phenotypes (albuminuria with preserved or reduced estimated glomerular filtration rate [eGFR]) as well as with eGFR categories or the nonalbuminuric DKD phenotype. Over a 7.4-year follow-up, unadjusted death rates and mortality risks increased progressively across eGDR tertiles, but remained significantly elevated after adjustment only in T3 vs T1 (age- and gender- adjusted death rate, 22.35 vs 16.74 per 1000 person-years, p < 0.0001, and hazard ratio [HR] adjusted for multiple confounders including DKD, 1.140 [95% confidence interval [CI], 1.049–1.238], p = 0.002). However, eGDR was independently associated with mortality in participants with no DKD (adjusted HR, 1.214 [95% CI, 1.072–1.375], p = 0.002) and in those with nonalbuminuric DKD (1.276 [1.034–1.575], p = 0.023), but not in those with the albuminuric DKD phenotypes. Moreover, the association was stronger in males and in younger individuals and was observed in those without but not with prior CVD, though interaction was significant only for age. Conclusions: The proxy of insulin sensitivity eGDR predicts all-cause mortality in type 2 diabetes, independent of confounders including DKD. However, the impact of IR in individuals with albuminuric DKD may be mediated by its relationship with albuminuria. Trial registration: ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July 2008.
AB - Background: It is unclear whether insulin resistance (IR) contributes to excess mortality in patients with type 2 diabetes independent of diabetic kidney disease (DKD), which is strongly associated with IR and is a major risk factor for cardiovascular disease (CVD), the main cause of death in these individuals. We tested this hypothesis in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events Italian Multicentre Study. Methods: This observational, prospective, cohort study enrolled 15,773 patients with type 2 diabetes attending 19 Italian Diabetes Clinics in 2006–2008. Insulin sensitivity was assessed as estimated glucose disposal rate (eGDR), which was validated against the euglycaemic-hyperinsulinemic clamp technique. Vital status on October 31, 2015, was retrieved for 15,656 patients (99.3%). Participants were stratified by eGDR tertiles from T1 (≥ 5.35 mg/kg/min) to T3 (≤ 4.14 mg/kg/min, highest IR). Results: CVD risk profile was worse in T2 and T3 vs T1. eGDR tertiles were independently associated with micro- and macroalbuminuria and the albuminuric DKD phenotypes (albuminuria with preserved or reduced estimated glomerular filtration rate [eGFR]) as well as with eGFR categories or the nonalbuminuric DKD phenotype. Over a 7.4-year follow-up, unadjusted death rates and mortality risks increased progressively across eGDR tertiles, but remained significantly elevated after adjustment only in T3 vs T1 (age- and gender- adjusted death rate, 22.35 vs 16.74 per 1000 person-years, p < 0.0001, and hazard ratio [HR] adjusted for multiple confounders including DKD, 1.140 [95% confidence interval [CI], 1.049–1.238], p = 0.002). However, eGDR was independently associated with mortality in participants with no DKD (adjusted HR, 1.214 [95% CI, 1.072–1.375], p = 0.002) and in those with nonalbuminuric DKD (1.276 [1.034–1.575], p = 0.023), but not in those with the albuminuric DKD phenotypes. Moreover, the association was stronger in males and in younger individuals and was observed in those without but not with prior CVD, though interaction was significant only for age. Conclusions: The proxy of insulin sensitivity eGDR predicts all-cause mortality in type 2 diabetes, independent of confounders including DKD. However, the impact of IR in individuals with albuminuric DKD may be mediated by its relationship with albuminuria. Trial registration: ClinicalTrials.gov, NCT00715481, retrospectively registered 15 July 2008.
KW - Albuminuria
KW - All-cause mortality
KW - Diabetic kidney disease
KW - Estimated glucose disposal rate
KW - Glomerular filtration rate
KW - Mellitus
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85102449873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102449873&partnerID=8YFLogxK
U2 - 10.1186/s12916-021-01936-3
DO - 10.1186/s12916-021-01936-3
M3 - Article
AN - SCOPUS:85102449873
VL - 19
JO - BMC Medicine
JF - BMC Medicine
SN - 1741-7015
IS - 1
M1 - 66
ER -